


## STATUS: ENROLLING GLOBALLY



The safety and efficacy of the agents and use under investigation have not been established.



A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of AG-120 in Combination With Azacitidine in Subjects  $\geq 18$  Years of Age With Previously Untreated Acute Myeloid Leukemia (AML) With an Isocitrate Dehydrogenase 1 (IDH1) Mutation

## PARTICIPATING COUNTRIES

- Australia
- Austria
- Brazil
- Canada
- China
- Czech Republic
- France
- Germany
- Israel
- Italy
- Japan
- Korea
- Mexico
- Netherlands
- Poland
- Russia
- Spain
- Taiwan
- United Kingdom
- United States



For additional details about Agios study AG120-C-009, including the study design, study location, or other information, please visit [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov) (Identifier: NCT03173248) or contact Agios Medical Information: email: [medinfo@agios.com](mailto:medinfo@agios.com); Phone: 833-228-8474.

IV0-US-0431 11/2019

